Home » Stocks » OPTN

OptiNose, Inc. (OPTN)

Stock Price: $4.06 USD -0.06 (-1.46%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
After-hours: $4.08 +0.02 (0.49%) Jan 20, 5:18 PM
Market Cap 209.88M
Revenue (ttm) 43.85M
Net Income (ttm) -100.92M
Shares Out 48.91M
EPS (ttm) -2.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $4.06
Previous Close $4.12
Change ($) -0.06
Change (%) -1.46%
Day's Open 4.17
Day's Range 4.02 - 4.20
Day's Volume 497,111
52-Week Range 3.20 - 9.01

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 4 weeks ago

YARDLEY, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Opti N ose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, toda...

GlobeNewsWire - 1 month ago

YARDLEY, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announ...

Seeking Alpha - 1 month ago

After COVID-19 slowed their commercial launch, OPTN is doing an exceptional job selling Xhance. Q3 2020 revenues grew ~50% from Q2 & consensus FY2021 revenue estimates forecast 100% growth. Pr...

Zacks Investment Research - 2 months ago

OptiNose (OPTN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Seeking Alpha - 2 months ago

OptiNose, Inc. (OPTN) CEO Peter Miller on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Preliminary X HANCE Net Revenue G rowth of 78% C ompared to Third Quarter 2019 and 50% C ompared to Second Quarter 2020

PRNewsWire - 3 months ago

YARDLEY, Pa., Sept. 29, 2020 /PRNewswire/ -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...

GlobeNewsWire - 4 months ago

YARDLEY, Pa., Sept. 14, 2020 (GLOBE NEWSWIRE) --   Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today ...

Seeking Alpha - 4 months ago

OptiNose has not performed well since its IPO and comes under more pressure, caused by the coronavirus.

The Motley Fool - 5 months ago

Some stock offerings dilute -- but not all.

Other stocks mentioned: NOVA, RMNI
Market Watch - 5 months ago

Shares of Optinose Inc. OPTN, +2.49% plunged 23% in premarket trading Friday, after the specialty pharmaceuticals company, focused on ear, nose, throat and allergy patients, said its stock off...

GlobeNewsWire - 5 months ago

YARDLEY, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced ...

GlobeNewsWire - 5 months ago

YARDLEY, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced ...

Seeking Alpha - 5 months ago

OptiNose, Inc. (OPTN) CEO Peter Miller on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

OptiNose (OPTN) delivered earnings and revenue surprises of -9.80% and -1.04%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

YARDLEY, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today an...

GlobeNewsWire - 5 months ago

YARDLEY, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today an...

GlobeNewsWire - 6 months ago

YARDLEY, Pa., July 08, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today an...

24/7 Wall Street - 6 months ago

OptiNose Inc. (NASDAQ: OPTN) shares popped on Tuesday after the company announced that it is making a move toward fighting COVID-19 with its tech.

GlobeNewsWire - 6 months ago

Company initiates development program using its EDS technology to deliver a nasal “antiseptic” intended to reduce illness and transmission of the COVID-19 virus Company initiates development p...

GlobeNewsWire - 6 months ago

YARDLEY, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today an...

GlobeNewsWire - 7 months ago

YARDLEY, Pa., June 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today an...

Seeking Alpha - 8 months ago

OptiNose, Inc. (OPTN) CEO Peter Miller on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

OptiNose, Inc. (OPTN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Seeking Alpha - 10 months ago

Optinose, Inc. (OPTN) CEO Peter Miller on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

OptiNose (OPTN) delivered earnings and revenue surprises of 13.43% and -11.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 11 months ago

YARDLEY, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today anno...

GlobeNewsWire - 1 year ago

YARDLEY, Pa., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today anno...

The Motley Fool - 1 year ago

A secondary offering resets the valuation of the ear, nose, and throat specialist.

Seeking Alpha - 1 year ago

Optinose, Inc.'s (OPTN) CEO Peter Miller on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InvestorPlace - 1 year ago

Investors are looking for the stocks that have the potential to lift their portfolios to new heights.

Other stocks mentioned: AMRN, CELH, EHTH, GTBIF, HIIQ, ZYNE
GlobeNewsWire - 1 year ago

YARDLEY, Pa., Oct. 04, 2019 (GLOBE NEWSWIRE) --   Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today re...

GlobeNewsWire - 1 year ago

YARDLEY, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today a...

GlobeNewsWire - 1 year ago

YARDLEY, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- OptiNose , Inc. (Optinose) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy sp...

GlobeNewsWire - 1 year ago

Company reiterates guidance for XHANCE net revenues for 2019 to be in the range of $29 - $34 million Company reiterates guidance for XHANCE net revenues for 2019 to be in the range of $29 - $3...

GlobeNewsWire - 1 year ago

YARDLEY, Pa., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today rep...

Benzinga - 1 year ago

OptiNose Inc’s (NASDAQ: OPTN) XHANCE nasal spray continued to exhibit encouraging trends in the second quarter, suggesting that the company's launch is progressing on track, according to RBC C...

Seeking Alpha - 1 year ago

OptiNose, Inc. (OPTN) CEO Peter Miller on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

OptiNose, Inc. (OPTN) CEO Peter Miller on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

OptiNose (OPTN) delivered earnings and revenue surprises of 1.41% and 2.99%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Benzinga - 1 year ago

OptiNose Inc. has introduced a new and simplified co-pay assistance program that's led to good script performance, according to Cantor Fitzgerald.

CNBC - 2 years ago

Optinose CEO: Building Awareness

Jim Cramer's always sniffing around for new investing ideas and he's caught the scent of an interesting new story in the medical device space. Don't miss his exclusive interview with the CEO o...

About OPTN

OptiNose, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It is also developing XHANCE, which is in Phase IIIb clinical trial for the treatment of chron... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Oct 13, 2017
CEO
Peter Miller
Employees
221
Stock Exchange
NASDAQ
Ticker Symbol
OPTN
Full Company Profile

Financial Performance

In 2019, OptiNose's revenue was $34.63 million, an increase of 390.18% compared to the previous year's $7.07 million. Losses were -$110.05 million, 3.18% more than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for OptiNose stock is "Buy." The 12-month stock price forecast is 17.00, which is an increase of 318.72% from the latest price.

Price Target
$17.00
(318.72% upside)
Analyst Consensus: Buy